Stock PV3B EYEPOINT PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings EyePoint Pharmaceuticals, Inc. Deutsche Boerse AG

Equities

PV3B

US30233G2093

Real-time Estimate Tradegate
Other stock markets
 11:46:02 01/07/2024 BST 		5-day change 1st Jan Change
8.103 EUR +0.09% Intraday chart for EyePoint Pharmaceuticals, Inc. +3.20% -63.14%
06-26 EyePoint Pharmaceuticals, Inc. Highlights Duravuyu Clinical and Regulatory Progress and Pipeline Innovation At R&D Day 2024 CI
06-26 Transcript : EyePoint Pharmaceuticals, Inc. - Special Call

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • Low profitability weakens the company.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
EYEPOINT PHARMACEUTICALS, INC. Stock EyePoint Pharmaceuticals, Inc.
-63.14% 453M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.32% 815B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+43.39% 641B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.75% 352B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+13.56% 314B
B-
ABBVIE INC. Stock AbbVie Inc.
+10.68% 303B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.13% 242B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+2.25% 224B
A+
NOVARTIS AG Stock Novartis AG
+13.37% 218B
B-
AMGEN INC. Stock Amgen Inc.
+8.48% 168B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. EYPT Stock
  4. PV3B Stock
  5. Ratings EyePoint Pharmaceuticals, Inc.